Inflammatory Bowel Disease (IBD) refers to conditions such as ulcerative colitis and Crohn's disease that are characterized by chronic inflammation of the intestine. Although the cause of IBD remains unknown, various features of the disease strongly suggest that autoimmunity is a major component of the pathogenesis. This suggests that Enzo's immune regulation technology platform may offer an effective treatment for IBD
IBD patients are currently managed during short-term episodes through the use of anti-inflammatory medications, or immunosuppressants such as corticosteroids. These provide symptomatic relief over short periods of time, but do not deliver a cure. These non-specific drugs all act by a generalized suppression of the immune response, with the unfortunate side effect of increasing the patient's susceptibility to infection. Enzo's drug candidate, AlequelT, is designed as a therapeutic modality that specifically quiets the inflammatory responses associated with IBD but does not induce a generalized immune suppression.
Approximately one million people in the United States suffer from IBD. In recent years the total treatment market exceeded 1.5 billion dollars.